The Evidence Base spoke with CP3's Dr. Inma Hernandez about her latest drug pricing paper in JAMA. The paper described the rise in the net costs of drugs, despite manufacturer discounts. "[T]he widening gap between list and net prices may be increasing disparities in health care access, because under-insured and uninsured patients are exposed to list prices,” Hernandez noted.